These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 1664791)

  • 1. A criterion for the adequacy of a simple design when a complex model will be used for analysis.
    Aickin M; Ritenbaugh C
    Control Clin Trials; 1991 Oct; 12(5):560-5. PubMed ID: 1664791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sample size calculations.
    Noordzij M; Dekker FW; Zoccali C; Jager KJ
    Nephron Clin Pract; 2011; 118(4):c319-23. PubMed ID: 21293154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Bayesian predictive sample size selection design for single-arm exploratory clinical trials.
    Teramukai S; Daimon T; Zohar S
    Stat Med; 2012 Dec; 31(30):4243-54. PubMed ID: 22807115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biostatistics in clinical trials: Part 2. Determining sample sizes for clinical trials.
    Ellenberg SS
    Oncology (Williston Park); 1989 Aug; 3(8):39-46; discussion 48, 51. PubMed ID: 2519197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnosing model diagnostics.
    Karlsson MO; Savic RM
    Clin Pharmacol Ther; 2007 Jul; 82(1):17-20. PubMed ID: 17571070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Flexible two-stage design with sample size reassessment for survival trials.
    Desseaux K; Porcher R
    Stat Med; 2007 Nov; 26(27):5002-13. PubMed ID: 17577242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimation in flexible two stage designs.
    Brannath W; König F; Bauer P
    Stat Med; 2006 Oct; 25(19):3366-81. PubMed ID: 16220489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-linearity of Parkinson's disease progression: implications for sample size calculations in clinical trials.
    Guimaraes P; Kieburtz K; Goetz CG; Elm JJ; Palesch YY; Huang P; Ravina B; Tanner CM; Tilley BC
    Clin Trials; 2005; 2(6):509-18. PubMed ID: 16422311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The need for more efficient trial designs.
    Golub HL
    Stat Med; 2006 Oct; 25(19):3231-5; discussion 3313-4, 3326-47. PubMed ID: 16819752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Equivalence and noninferiority testing in regression models and repeated-measures designs.
    Mascha EJ; Sessler DI
    Anesth Analg; 2011 Mar; 112(3):678-87. PubMed ID: 21304155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Power and sample size for clinical trials when efficacy is required in multiple endpoints: application to an Alzheimer's treatment trial.
    Xiong C; Yu K; Gao F; Yan Y; Zhang Z
    Clin Trials; 2005; 2(5):387-93. PubMed ID: 16317808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sample size for equivalence trials: a case study from a vaccine lot consistency trial.
    Ganju J; Izu A; Anemona A
    Stat Med; 2008 Aug; 27(19):3743-54. PubMed ID: 18416439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Group sequential and discretized sample size re-estimation designs: a comparison of flexibility.
    Wu X; Cui L
    Stat Med; 2012 Oct; 31(24):2844-57. PubMed ID: 22733405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. When was a "negative" clinical trial big enough? How many patients you needed depends on what you found.
    Detsky AS; Sackett DL
    Arch Intern Med; 1985 Apr; 145(4):709-12. PubMed ID: 3985731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An examination of the efficiency of the sequential parallel design in psychiatric clinical trials.
    Tamura RN; Huang X
    Clin Trials; 2007; 4(4):309-17. PubMed ID: 17848492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A convenient formula for sample size calculations in clinical trials with multiple co-primary continuous endpoints.
    Sugimoto T; Sozu T; Hamasaki T
    Pharm Stat; 2012; 11(2):118-28. PubMed ID: 22415870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Some design issues of strata-matched non-randomized studies with survival outcomes.
    Mazumdar M; Tu D; Zhou XK
    Stat Med; 2006 Dec; 25(23):3949-59. PubMed ID: 16596571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Power and sample size.
    Case LD; Ambrosius WT
    Methods Mol Biol; 2007; 404():377-408. PubMed ID: 18450060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adaptive group sequential test for clinical trials with changing patient population.
    Feng H; Shao J; Chow SC
    J Biopharm Stat; 2007; 17(6):1227-38. PubMed ID: 18027228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal timing for interim analyses in clinical trials.
    Togo K; Iwasaki M
    J Biopharm Stat; 2013; 23(5):1067-80. PubMed ID: 23957516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.